DUBLIN–(BUSINESS WIRE)–The “Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 40, 42, 1, 5, 143, 49 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.
Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Non-Alcoholic Steatohepatitis (NASH) – Overview
- Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Development
- Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Assessment
- Non-Alcoholic Steatohepatitis (NASH) – Companies Involved in Therapeutics Development
- Non-Alcoholic Steatohepatitis (NASH) – Drug Profiles
- Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects
- Non-Alcoholic Steatohepatitis (NASH) – Discontinued Products
- Non-Alcoholic Steatohepatitis (NASH) – Product Development Milestones
- Appendix
Companies Mentioned
- 3-V Biosciences Inc
- 89bio Ltd
- Abide Therapeutics Inc
- AdAlta Ltd
- Akcea Therapeutics Inc
- Akero Therapeutics Inc
- Albireo Pharma Inc
- Aldeyra Therapeutics Inc
- Allergan Plc
- Allinky Biopharma SL
- Alteogen Inc
- Angion Biomedica Corp
- Araim Pharmaceuticals Inc
- Arcturus Therapeutics Ltd
- Ardelyx Inc
- Ascletis Inc
- Assembly Biosciences Inc
- AstraZeneca Plc
- Betagenon AB
- BioElectron Technology Corp
- Bird Rock Bio Inc
- BLR Bio LLC
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Cadila Healthcare Ltd
- Can-Fite BioPharma Ltd
- Carmot Therapeutics Inc
- Celgene Corp
- Cerenis Therapeutics Holding SA
- ChemoCentryx Inc
- CJ HealthCare Corp
- CohBar Inc
- Coherus BioSciences Inc
- ConSynance Therapeutics Inc
- ContraVir Pharmaceuticals Inc
- Corcept Therapeutics Inc
- CymaBay Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Debiopharm International SA
- Dicerna Pharmaceuticals Inc
- Dimerix Bioscience Pty Ltd
- Dong-A Socio Holdings Co Ltd
- DURECT Corp
- Eli Lilly and Co
- Enanta Pharmaceuticals Inc
- Enyo Pharma SA
- Esperion Therapeutics Inc
- Exicure Inc
- Forma Therapeutics Inc
- Galectin Therapeutics Inc
- Galecto Biotech AB
- Galmed Pharmaceuticals Ltd
- Gemphire Therapeutics Inc
- Genfit SA
- GenKyoTex SA
- Gilead Sciences Inc
- GRI Bio Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Hana Pharm Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- HemoShear Therapeutics, LLC
- HotSpot Therapeutics Inc
- IB Pharmaceuticals Inc
- Immupharma Plc
- Immuron Ltd
- Indalo Therapeutics Inc
- Integral Molecular Inc
- Intercept Pharmaceuticals Inc
- Inventiva
- Inversago Pharma Inc
- Ionis Pharmaceuticals Inc
- Kowa Co Ltd
- Kyorin Pharmaceutical Co Ltd
- LG Chem Ltd
- LifeMax Laboratories Inc
- Lin Bioscience Inc
- Lipocine Inc
- Madrigal Pharmaceuticals Inc
- MallInckrodt Plc
- MedImmune LLC
- Merck & Co Inc
- Metabolys SAS
- Metacrine Inc
- Mina Therapeutics Ltd
- Mitsubishi Tanabe Pharma Corp
- Naia Ltd
- Nash Pharmaceuticals Inc
- NeuroVive Pharmaceutical AB
- NGM Biopharmaceuticals Inc
- Nippon Chemiphar Co Ltd
- Novartis AG
- Novo Nordisk AS
- Nuevolution AB
- NuSirt Biopharma Inc
- Oramed Pharmaceuticals Inc
- Pfizer Inc
- Phanes Therapeutics Inc
- Pharmaxis Ltd
- Phenex Pharmaceuticals AG
- Pliant Therapeutics Inc
- Poxel SA
- Promethera Biosciences SA
- ProMetic Life Sciences Inc
- Protalix BioTherapeutics Inc
- Redx Pharma Plc
- Regulus Therapeutics Inc
- reMYND NV
- Ritter Pharmaceuticals Inc
- Saje Pharma LLC
- Sancilio & Company Inc
- Sanofi
- ScandiCure AB
- Second Genome Inc
- Seres Therapeutics Inc
- SFA Therapeutics LLC
- Shenzhen HighTide Biopharmaceutical Ltd
- Sihuan Pharmaceutical Holdings Group Ltd
- Synlogic Inc
- T3D Therapeutics Inc
- TaiwanJ Pharmaceuticals Co Ltd
- Terns Pharmaceuticals Inc
- Tiziana Life Sciences Plc
- TRACON Pharmaceuticals Inc
- Vascular Biogenics Ltd
- Verlyx Pharma Inc
- Viking Therapeutics Inc
- Visionary Pharmaceuticals Inc
- Vivus Inc
- WAVE Life Sciences Ltd
- Yuhan Corp
- Zafgen Inc
- Zebra Discovery Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bmrq11
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs